VAP-1 Targeting Peptides for Inflammatory Disease Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for inhibiting VAP-1 activity, a key molecule in leukocyte trafficking and inflammation, are limited in specificity and effectiveness, particularly in targeting VAP-1 for therapeutic interventions.
Innovation Solution
Development of peptides, such as CVKWRGVVVC, identified through phage display technology, which bind specifically to VAP-1, enabling targeted therapeutic and diagnostic approaches by facilitating the localization of VAP-1 and modulating its activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional inhibition strategies (monoclonal antibodies, enzyme inhibitors) are used to target VAP-1, then VAP-1 activity can be inhibited, but the specificity and effectiveness for therapeutic interventions are limited
Solution Approach 1:
The patent changes the molecular parameters of the targeting agent by using peptide sequences (such as CVKWRGVVVC) derived from phage display libraries instead of conventional antibodies or small molecule inhibitors. These peptides exhibit enhanced binding affinity and specificity to VAP-1, thereby improving both reliability and adaptability for therapeutic applications.
Solution Approach 2:
The patent employs phage display technology to generate and screen large libraries of peptide sequences, effectively copying and testing numerous potential ligands until optimal binders are identified. This systematic copying approach enables the discovery of peptides with superior specificity and therapeutic potential compared to conventional inhibitors.
2Measurement precision
If phage display technology is used to identify peptide ligands for VAP-1, then binding specificity is improved, but the complexity of the screening process increases
Solution Approach 1:
The patent extracts and sequences the peptide sequences from the phage display library that bind to VAP-1. By isolating and analyzing only the successful binders, the method achieves high measurement precision in identifying specific ligands while managing the complexity through focused analysis rather than exhaustive screening.
Solution Approach 2:
The patent uses phage particles as intermediary carriers to display peptide sequences on their surface. This intermediary system enables the peptides to be presented to VAP-1 in a controlled manner, facilitating specific binding detection while simplifying the overall screening process compared to direct peptide testing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively target VAP-1, inhibiting its enzymatic activity and facilitating leukocyte binding, providing a precise mechanism for treating and preventing VAP-1-related inflammatory and vascular diseases.
Implementation Method 1
The peptides bind to VAP-1 (Vascular Adhesion Protein-1)
Implementation Method 2
VAP-1 is an ecto-enzyme. Analysis of the VAP-1 MAO activity showed that VAP-1 belongs to the class of membrane-bound MAO's termed semicarbazide-sensitive amine oxidases (SSAO). These are distinguished from the widely distributed mitochondrial MAO-A and B flavoproteins by amino acid sequence, cofactor, substrate specificity and sensitivity to certain inhibitors.
Data Source
Figure 1A~1B
Figure 2
Figure 3A~3B
AI summary
This invention relates to novel peptides, discovered by using phage display technique, that bind to VAP-1 (Vascular Adhesion Protein-1). The invention concerns also peptides useful as VAP-1 ligands. Such peptides constitute a portion of natural proteins that are present in the individual. The invention relates particularly to a peptide chain in the leukocyte surface protein, where said peptide chain is useful as a ligand for the VAP-1 molecule and thus facilitates the binding of leukocytes to the vascular endothelium. Furthermore, the invention relates to pharmaceutical and diagnostic compositions for targeting VAP-1 in vivo.